Eye disorders in diabetes: potential drug targets
- PMID: 18537702
- DOI: 10.2174/187152608784746529
Eye disorders in diabetes: potential drug targets
Abstract
Diabetes Mellitus (DM) is a serious medical problem that causes long-term systemic complications and considerable associated morbidity. DM can cause retinopathy (DRP), maculopathy, cataract, optic neuropathy, defects of eye muscles. DM is a risk factor for acute infectious conjunctivitis, bacterial keratitis, herpes virus infections and endophtalmitis. Elevated blood glucose induces structural, physiological and hormonal changes which affect retinal capillaries. DRP is recognized by loss of pericyte function and capillary occlusions together leading to breakdown of blood-retinal barrier, edematous changes and proliferation of vessels and fibrous tissue. Depending on stage of DRP, there are different preferable therapeutic approaches applied. In the case of ETDRS, in the area of leakage focal treatment should be performed, while panretinal photocoagulation is applied towards ischemic areas or beginning proliferations. Vitreal haemorrhage followed by fibroproliferative changes or tractional retinal detachment is treated by vitrectomy alone or in combination with ILM peeling. In pathogenesis of DRP, Insulin Growth Factor (IGF-1) can play an important role in production of VEGF (Vascular Endothelial Growth Factor). Hypoxia can up-regulate VEGF expression levels leading to pathologic ocular neovascularisation. An application of intravitreal corticosteroid treatment modulates vascular permeability by suppressing the production of VEGF, reducing both extracellular matrix metalloproteinase activity and basic fibroblast growth factor, decreasing major histocompatibility complex 2 Ag expression levels, and inhibiting activity of inflammatory cells. Clinical effects of treatment using intravitreal corticosteroids are evaluated by reduction of macular thickness and visual improvement. Intravitreal use of Anti-VEGF drugs, Pegaptanib, Ranibizumab and Bevacizumab can modify vasoproliferation, trigger macular edema, and, therefore, influence a prognosis for visual loss.
Similar articles
-
The area of fixation covaries with short-term changes in visual acuity after anti-vascular endothelial growth factor treatment in patients with diabetic macular oedema.Acta Ophthalmol. 2018 Nov;96(7):744-748. doi: 10.1111/aos.13773. Epub 2018 Apr 24. Acta Ophthalmol. 2018. PMID: 29687595
-
Vascular endothelial growth factor and diabetic macular edema.Surv Ophthalmol. 2016 Nov-Dec;61(6):759-768. doi: 10.1016/j.survophthal.2016.03.010. Epub 2016 Apr 1. Surv Ophthalmol. 2016. PMID: 27045225 Review.
-
[Diabetic maculopathy].Ophthalmologe. 2015 Oct;112(10):871-83; quiz 884-6. doi: 10.1007/s00347-015-0127-2. Ophthalmologe. 2015. PMID: 26420681 Review. German.
-
Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab.Br J Ophthalmol. 2016 Mar;100(3):365-70. doi: 10.1136/bjophthalmol-2014-306482. Epub 2015 Jul 17. Br J Ophthalmol. 2016. PMID: 26187951 Free PMC article.
-
Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.Retina. 2008 Oct;28(8):1053-60. doi: 10.1097/IAE.0b013e318176de48. Retina. 2008. PMID: 18779710
Cited by
-
Oxidative stress and diabetic retinopathy: development and treatment.Eye (Lond). 2017 Aug;31(8):1122-1130. doi: 10.1038/eye.2017.64. Epub 2017 Apr 28. Eye (Lond). 2017. PMID: 28452994 Free PMC article. Review.
-
Ocular surface changes in type II diabetic patients with proliferative diabetic retinopathy.Int J Ophthalmol. 2015 Apr 18;8(2):358-64. doi: 10.3980/j.issn.2222-3959.2015.02.26. eCollection 2015. Int J Ophthalmol. 2015. PMID: 25938056 Free PMC article.
-
Outcomes of microincision vitrectomy surgery with internal limiting membrane peeling for macular edema secondary to branch retinal vein occlusion.Clin Ophthalmol. 2015 Mar 4;9:439-44. doi: 10.2147/OPTH.S75659. eCollection 2015. Clin Ophthalmol. 2015. PMID: 25784789 Free PMC article.
-
Cancer biology in diabetes.J Diabetes Investig. 2014 May 4;5(3):251-64. doi: 10.1111/jdi.12208. Epub 2014 Mar 5. J Diabetes Investig. 2014. PMID: 24843770 Free PMC article. Review.
-
Renal vascular structure and rarefaction.Compr Physiol. 2013 Apr;3(2):817-31. doi: 10.1002/cphy.c120012. Compr Physiol. 2013. PMID: 23720331 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous